On April 18th, according to a report by Market Watch, the Italian Competition Authority (AGCM) launched an investigation into British American Tobacco (BAT) and Amazon, citing claims that the two companies have been providing misleading information in their advertising for new heated tobacco devices.
The Italian competition watchdog announced that the advertising campaign for the glo hyper X2 product, owned by British American Tobacco, inaccurately suggested that the product is nicotine-free. The advertisement was disseminated on Amazon, and could potentially pose health risks to some consumers, particularly minors.
Currently, neither British American Tobacco nor Amazon have responded to the issue.
Further reading:
British American Tobacco responds to 2FIRSTS: Testing of disposable e-cigarettes in the UK is a valid concern.
British and American tobacco companies are suspected of initiating an anti-ban movement against electronic cigarettes in Australia. The related videos have been removed.
The IBVTA says that any harm reduction claims made by BAT should be questioned.
Legal Expert Op-Ed: BAT Cannot Serve as Enforcement Police for E-Cigarettes
BAT has launched a pop-up store called "Glo studio" in South Korea to kick off a new product experience event.
References:
Amazon and British American Tobacco are under investigation in Italy for their promotion of heated tobacco devices through advertising.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
